Semaglutide produced 14.9% mean weight loss in STEP-1 at 68 weeks
Tirzepatide and oral contraceptives in obesity: switch to a non-oral contraceptive or barrier method for 4 weeks after initiation or dose escalation
Based on the available preclinical research and practitioner experience, patients typically explore BPC-157 for the following concerns: BPC-157 is not a replacement for medical treatment
Finally, given the robust adipose remodeling observed here, it will be essential to evaluate whether similar molecular and metabolic adaptations occur in human adipose depots, which differ from rodents in distribution and responsiveness
You also shouldnt rely on tirzepatide without supporting habits like hydration, balanced eating, and movement
As the CMO, she helps train and educate all practitioners within the BodyLogicMD network